Many types of biologics have been approved by the US Food and Drug Administration, including monoclonal antibodies (eg, adalimumab [Humira]), therapeutic proteins (eg, filgrastim [Neupogen]), and vaccines (eg, agents used for tetanus and influenza). In 2018, sales of biologics totaled approximately $125 billion, reflecting an increase of 50% from 2014 figures.1 Biologics coordinators play a central role in overcoming challenges to patient access to these agents by navigating benefits, communicating with insurance companies, and advocating for individual patients.
Read Now
Stay up to date with dermatology news & updates by subscribing to receive the free DPM print publications or e‑Newsletters.